Penumbra Q4 EPS Tops Estimates by 5.36% with 22.1% Revenue Growth
Penumbra delivered Q4 EPS of $1.18, beating estimates by 5.36%, and reported $385.4M in revenue, up 22.1% year-over-year and 6.74% above forecasts. UBS set a $374 price target implying a 9.9% upside, supported by U.S. sales rising 20.6% and international revenue jumping 27.7%.
1. Strong Fourth-Quarter Results
Penumbra reported EPS of $1.18, surpassing estimates by 5.36%, and delivered $385.39 million in revenue, marking 22.1% year-over-year growth and beating forecasts by 6.74%. This represents a significant improvement from $0.97 per share and $315.52 million in revenue a year earlier.
2. Geographic Revenue Breakdown
U.S. operations generated 77.6% of total revenue, with sales up 20.6%, while international markets contributed 22.4% and saw revenue surge 27.7%. Global thrombectomy product sales reached $254.7 million, driven by robust performance across key regions.
3. Investor Outlook and Stock Performance
Analysts set a $374 price target, suggesting roughly 9.9% upside from the current ~$340 share price. The stock trades near its 52-week high of $362.41 with a $13.38 billion market capitalization, reflecting strong market confidence in Penumbra’s growth trajectory.